Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > News > Canaccord Adams Initiates Coverage on AMAG Pharmaceuticals (AMAG) with a Buy

October 16th, 2008

Canaccord Adams Initiates Coverage on AMAG Pharmaceuticals (AMAG) with a Buy

Abstract:
Canaccord Adams initiates coverage on AMAG Pharmaceuticals (Nasdaq: AMAG) with a Buy rating and $57 target.

Canaccord analyst says, "Binary event but we believe data should enable first cycle approval...We acknowledge that there is controversy about whether AMAG has generated enough data for ferumoxytol approval. We believe that the Phase 3 studies demonstrated the strong efficacy and (more importantly) clean safety profile of ferumoxytol in CKD patients. We think that data also suggests that ferumoxytol may have the best safety profile, and importantly the lowest rates of anaphylaxis, of all the IV iron therapies. However, given the conservative FDA environment, we recognize that AMAG could receive a late approval or a request for more data...We believe that AMAG shares offer a compelling risk/benefit profile. AMAG shares are down almost 50% from their 52-week high in October 2007. We base our $57 price target on a pNPV analysis that assumes a 50% probability of a first-cycle approval for ferumoxytol. If ferumoxytol is approved, our pNPV analysis would yield a $95 value. If the FDA requests an additional study, our pNPV analysis would yield a $25 value."

Source:
streetinsider.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Industrial Nanotech, Inc. to Publish PCAOB Audited Financials July 31st, 2014

Nanostructured metal-oxide catalyst efficiently converts CO2 to methanol: Highly reactive sites at interface of 2 nanoscale components could help overcome hurdle of using CO2 as a starting point in producing useful products July 31st, 2014

Carnegie Mellon Chemists Create Nanofibers Using Unprecedented New Method July 31st, 2014

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

Investments/IPO's/Splits

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

Harris & Harris Group Invests in Unique NYC Biotech Accelerator July 29th, 2014

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014

Nanometrics Announces Upcoming Investor Events July 22nd, 2014

Nanomedicine

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014

Announcements

Industrial Nanotech, Inc. to Publish PCAOB Audited Financials July 31st, 2014

Nanostructured metal-oxide catalyst efficiently converts CO2 to methanol: Highly reactive sites at interface of 2 nanoscale components could help overcome hurdle of using CO2 as a starting point in producing useful products July 31st, 2014

Carnegie Mellon Chemists Create Nanofibers Using Unprecedented New Method July 31st, 2014

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE